SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
193
- +33 vs. Q1 2026
- Total value $1.08B
Superinvestors holding SLS
0
- None of the superinvestors held SLS at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by SLS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Nov 19, 2025 | Kalin Katherine BachDirector | PPurchaseCommon Stock | +63.4K | $1.59 | +$100.81K | 104.4K | +154.6% | SEC |
| Jun 13, 2025 | Jun 12, 2025 | VAN NOSTRAND ROBERT LDirector | PPurchaseCommon Stock | +10K | $1.48 | +$14.8K | 20.4K | +96.2% | SEC |
| Jun 2, 2025 | May 30, 2025 | Wasman JaneDirector | PPurchaseCommon Stock | +20K | $1.69 | +$33.8K | 30.4K | +192.3% | SEC |
| May 22, 2025 | May 22, 2025 | Kalin Katherine BachDirector | PPurchaseCommon Stock | +20K | $1.80 | +$36K | 41K | +95.2% | SEC |
| Dec 5, 2022 | Dec 5, 2022 | Stergiou Angelos M.President and CEO | SSaleClass A Common Stock | −6.49K | $2.61 | −$16.95K | 161.69K | −3.9% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in SLS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15,070,302 | $222.44M | 0.00% | +2,871,892+23.5% | Added |
| STATE STREET CORP | 12,996,558 | $191.83M | 0.01% | +4,600,202+54.8% | Added |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,226,105 | $121.42M | 0.00% | +700,176+9.3% | Added |
| GEODE CAPITAL MANAGEMENT, LLC | 4,884,175 | $72.11M | 0.00% | +971,569+24.8% | Added |
| Anson Funds Management LP | 4,500,000 | $66.42M | 6.05% | +4,500,000 | New |